ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
US Tech 100
17,244.80
1.57%
Dow Jones
38,239.66
0.40%
Brent Oil
88.165
0.00%
Bitcoin
63,170.40
-0.89%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Cartesian Therapeutics Inc (RNAC) Quote

Cartesian Therapeutics Inc

Cartesian Therapeutics Inc (RNAC)

NASDAQ
21.03
0.13
(0.62%)
Closed April 27 4:00PM
Delayed by 15 minutes
21.10
0.07
(0.33%)
After Hours: 7:59PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
21.03
Bid
19.25
Ask
21.79
Volume
123,840
20.71 Day's Range 21.74
11.665 52 Week Range 42.60
Market Cap
3.417B
Previous Close
20.90
Open
20.90
Last Trade
3
@
21.5
Last Trade Time
Financial Volume
$ 2,625,490
VWAP
21.2007
Average Volume (3m)
560,253
Shares Outstanding
161,948,618
Dividend Yield
-
PE Ratio
-15.55
Earnings Per Share (EPS)
-1.36
Revenue
26M
Net Profit
-219.71M

About Cartesian Therapeutics Inc

Selecta Biosciences Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL... Selecta Biosciences Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL-313 for Ornithine Transcarbamylase Deficiency (OTC), and others. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.selectabio.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Cartesian Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RNAC. The last closing price for Cartesian Therapeutics was $20.90. Over the last year, Cartesian Therapeutics shares have traded in a share price range of $ 11.665 to $ 42.60.

Cartesian Therapeutics currently has 161,948,618 shares outstanding. The market capitalization of Cartesian Therapeutics is $3.42 billion. Cartesian Therapeutics has a price to earnings ratio (PE ratio) of -15.55.

RNAC Latest News

More News

Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that recently reported...

April 22 2024
Business Wire

Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that its management...

April 04 2024
Business Wire

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the...

April 04 2024
Business Wire

Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split

GAITHERSBURG, Md., March 28, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for...

March 28 2024
GlobeNewswire Inc.

Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis (MG) remains on track for mid-2024 On track to initiate...

March 07 2024
GlobeNewswire Inc.

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for...

March 06 2024
GlobeNewswire Inc.

Cartesian Therapeutics Announces New Employment Inducement Grant

GAITHERSBURG, Md., March 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the...

March 05 2024
GlobeNewswire Inc.

Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland

New facility expected to support expanded cGMP manufacturing of clinical and commercial supply of Company’s pipeline of mRNA cell therapies for the treatment of autoimmune diseases GAITHERSBURG...

March 05 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
13.9523.126463700217.0821.7416.98510675319.99032524CS
41.537.8461538461519.521.7411.66533952316.09935158CS
12-0.642-2.9623477297921.67224.1511.66556025319.3594623CS
26-3.165-13.081215127124.19542.611.66574611923.41872539CS
52-3.165-13.081215127124.19542.611.66574611923.41872539CS
156-3.165-13.081215127124.19542.611.66574611923.41872539CS
260-3.165-13.081215127124.19542.611.66574611923.41872539CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BDRXBiodexa Pharmaceuticals PLC
$ 1.3254
(82.86%)
70.82M
IBRXImmunityBio Inc
$ 7.35
(43.84%)
40.28M
AGENAgenus Inc
$ 11.685
(40.78%)
3.37M
ULHUniversal Logistics Holdings Inc
$ 45.63
(38.74%)
484.22k
NIVFNewGenIvf Group Ltd
$ 1.77
(36.15%)
57.78M
MFImF International Ltd
$ 2.3153
(-77.82%)
21.23M
NWGLNature Wood Group Ltd
$ 5.05
(-70.03%)
2.48M
ICLKiClick Interactive Asia Group Ltd
$ 1.21
(-52.17%)
719.95k
NUWENewellis Inc
$ 0.1695
(-41.35%)
18.46M
SGBXSafe and Green Holdings Corporation
$ 0.1469
(-32.92%)
8.39M
PEGYPineapple Energy Inc
$ 0.065499
(26.20%)
325.57M
SQQQProShares UltraPro Short QQQ
$ 11.43
(-4.75%)
137.28M
INTCIntel Corporation
$ 31.88
(-9.20%)
119.84M
TSLATesla Inc
$ 168.29
(-1.11%)
109.84M
SOFISoFi Technologies Inc
$ 7.87
(3.69%)
88.63M

Discussion

View Full Feed
misterfishman misterfishman 1 minute ago
I hope so bro.
IGPK
pos_stock_hoarder pos_stock_hoarder 2 minutes ago
Steppenwolf - America

https://youtu.be/3REXu1ZO3BY
Stockman1010101 Stockman1010101 2 minutes ago
hello folks. Better days are here to come.
pos_stock_hoarder pos_stock_hoarder 3 minutes ago
Steppenwolf - America (OK, we need some new lyrics but the question remains: America, Where are you Now?)

https://youtu.be/3REXu1ZO3BY
BADALI BADALI 4 minutes ago
$IGPK : JFHE I am not worry about anything. They can sell and they will buy again because all DD is solid here. They are day trader or swing traders both are in red now because they get in and not able to take profit.
1M shares are enough to change the life style.
Long and Strong here.
IGPK
learningcurve2020 learningcurve2020 4 minutes ago
It's not GBM or he wouldn't be getting back to work. Likely prostate, IMO.


>>The type of cancer has not been disclosed, but the King's medical team are "sufficiently pleased with the progress made so far that the King is now able to resume a number of public-facing duties".
NWBO
newmedman newmedman 6 minutes ago
https://twitter.com/InternetH0F/status/1784319122370699664
yp_1 yp_1 7 minutes ago
Re: “but i would expect he has some vested interest in this atleast morally”. There is no morality in play when it comes to money, and we all know that.
SEV
DewDiligence DewDiligence 9 minutes ago
WY 1Q24 CC transcript:

https://finance.yahoo.com/news/q1-2024-weyerhaeuser-co-earnings-043100673.html
WY
TRADER99 TRADER99 9 minutes ago
https://twitter.com/pennytrader99/status/1784331001893675481?t=TmRoWnFzwUuj67UETclw4A&s=19
CIVX
fuagf fuagf 9 minutes ago
Who are you voting for? For "Voting for closing the borders" - a stupid, disingenuous, empty conservative slogan -- Trump
and his MAGAs are blocking the present bipartisan bill. Who are you voting for? Who. Trump for the 3rd time, eh.
DewDiligence DewDiligence 10 minutes ago
CVC 1Q24 CC transcript:

https://finance.yahoo.com/news/q1-2024-chevron-corp-earnings-052034830.html
CVX
condor1 condor1 11 minutes ago
Read my posts to Benny, you BSer.
AABB
DewDiligence DewDiligence 11 minutes ago
ABBV 1Q24 CC transcript:

https://finance.yahoo.com/news/q1-2024-abbvie-inc-earnings-052453398.html
ABBV
SorcererDiviner18 SorcererDiviner18 11 minutes ago
Still no replies to my other posts.

This will be my last post here.

No quality DD and waste of time.
BEGI
DewDiligence DewDiligence 12 minutes ago
…last month they announced they had a minimum price of $900. Over the last two weeks I was buying in the range of $7.90 to $8.10.Is there a typo there with respect to the decimal point?
BeverlyH BeverlyH 12 minutes ago
The SEC will hopefully flush out all the nonsense. I'll put a marker down here: Parkinson will not be able to obtain SEC approval on any Form 10 in 2024 - $100 for anyone that wants that bet; bonus another $100 that Myflix will not launch in 2024. The $300 parlay includes no release to 1100+ thea
HHSE
Eli's Gone Eli's Gone 12 minutes ago
GL youse guys...
yp_1 yp_1 12 minutes ago
Why would one expect orders at this point in time? The qualifications are not complete yet. It takes 6 months, so we are looking at July as the earliest. And this was known when they announced the start of the qualification process in January.
SEV
yp_1 yp_1 12 minutes ago
Why would one expect orders at this point in time? The qualifications are not complete yet. It takes 6 months, so we are looking at July as the earliest. And this was known when they announced the start of the qualification process in January.
SEV

Your Recent History

NASDAQ
RNAC
Cartesian Therapeutics
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved